Insight Molecular Diagnostics (IMDX) Return on Equity (2016 - 2026)

Insight Molecular Diagnostics (IMDX) has 11 years of Return on Equity data on file, last reported at 0.0% in Q1 2026.

• Quarterly Return on Equity fell 10.0% year-over-year to 0.0% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.0% (down 10.0% YoY) and the FY2025 annual result came in at 0.0%, up 4.0% from the prior year.
• Return on Equity eased to 0.0% in Q1 2026 per IMDX's latest filing, from 0.01% in the prior quarter.
• The five-year high for Return on Equity was 0.1% in Q1 2025, with the low at 0.03% in Q2 2025.
• Average Return on Equity over 5 years is 0.01%, with a median of 0.01% recorded in 2024.
• Year-over-year, Return on Equity grew 11 bps in 2025 and slipped 10 bps in 2026.
• Insight Molecular Diagnostics' Return on Equity stood at 0.01% in 2022, then soared by 89 bps to 0.0% in 2023, then jumped by 9612 bps to 0.1% in 2024, then slumped by 95 bps to 0.01% in 2025, then decreased by 25 bps to 0.0% in 2026.
• Business Quant data shows IMDX's Return on Equity at 0.0% in Q1 2026, 0.01% in Q4 2025, and 0.03% in Q3 2025.